US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Neo-Concept International Group Holdings Limited

0.3175

-0.0003-0.09%

Pre-market: 0.32000.00000.00%08:00 EDT

Volume:29.86K

Turnover:9.30K

Market Cap:6.45M

PE:4.16

High:0.3280

Open:0.3200

Low:0.3000

Close:0.3178

Loading ...

Overview Company News Filings

SELLAS Announces Key Business Objectives for 2025

Gain Therapeutics Announces Formation of Clinical Advisory Board to Support Continued Advancement of Lead Drug Candidate GT-02287

Shell fourth quarter 2024 update note

Guardant Health Shield test selected for use in NCI Vanguard study

MD Anderson and Myriad Genetics form strategic alliance to evaluate clinical utility of Myriad’s molecular residual disease assay

BerGenBio Announces First Patient Entered Into Advanced Adenocarcinoma Lung Cancer Trial

Neo-Concept International Group Holdings First Half 2024 Earnings: EPS: HK$0.075 (vs HK$0.29 loss in 1H 2023)

Simply Wall St.

Neo-Concept International Group H1 2024 EPS $0.01; Revenue $10.15M

Neo-Concept International Group Holdings Limited Announces First Half 2024 Unaudited Financial Results

THOMSON REUTERS

Plus Therapeutics Presents Positive ReSPECT-LM Phase 1 Interim Data for Breast Cancer Patients with Leptomeningeal Metastases at the 2024 San Antonio Breast Cancer Symposium

LYNPARZA® (olaparib) demonstrated clinically meaningful prolonged survival benefit in early breast cancer in OlympiA Phase III trial

Press Release: Shell plc Third Quarter 2024 Euro and GBP Equivalent Dividend Payments

BLINCYTO® (BLINATUMOMAB) ADDED TO CHEMOTHERAPY SIGNIFICANTLY IMPROVES SURVIVAL IN NEWLY DIAGNOSED PEDIATRIC PATIENTS WITH B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL)

Plus Therapeutics to Showcase ReSPECT-LM Phase 1 Interim Data for Leptomeningeal Metastases at the 2024 San Antonio Breast Cancer Symposium

Press Release: Shell completes sale of Sinco pipeline system and Colex terminal to Edgewater Midstream

Kairos Pharma Adds City of Hope Cancer Center for Phase 2 ENV105 Clinical Trial

Aptose and NCI Collaborate on Cancer Drug Trials

BRIEF-Aptose Signs CRADA with NCI to Develop Tuspetinib for AML and MDS in Newly Launched MyeloMATCH Precision Medicine Trials

Aptose Biosciences signs CRADA with NCI to develop tuspetinib for AML, MDS

Plus Therapeutics Expands Strategic Agreement with Telix IsoTherapeutics Group for Rhenium-186 Radioisotope Supply

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/NCI/news?page=4"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"NCI","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NCI\",,,,,undefined,":{"symbol":"NCI","market":"US","secType":"STK","nameCN":"Neo-Concept International Group Holdings Limited","latestPrice":0.3175,"timestamp":1746561600000,"preClose":0.3178,"halted":0,"volume":29864,"hourTrading":{"tag":"盘前","latestPrice":0.32,"preClose":0.32,"latestTime":"08:00 EDT","volume":164,"amount":52.480000000000004,"timestamp":1746619207661},"delay":0,"floatShares":1726200,"shares":20320000,"eps":0.076408,"marketStatus":"Pre-Mkt","change":-0.0003,"latestTime":"05-07 09:26:07 EDT","open":0.32,"high":0.328,"low":0.3,"amount":9297.97632008,"amplitude":0.088106,"askPrice":0.416,"askSize":200,"bidPrice":0.2107,"bidSize":200,"shortable":3,"etf":0,"ttmEps":0.076408,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1746624600000},"marketStatusCode":1,"adr":0,"adrRate":0,"listingDate":1713844800000,"exchange":"NASDAQ","adjPreClose":0.32,"dividendRate":0.629921,"preHourTrading":{"tag":"盘前","latestPrice":0.32,"preClose":0.32,"latestTime":"08:00 EDT","volume":164,"amount":52.480000000000004,"timestamp":1746619207661},"postHourTrading":{"tag":"盘后","latestPrice":0.312,"preClose":0.3175,"latestTime":"18:29 EDT","volume":5532,"amount":1736.06,"timestamp":1746570546435},"volumeRatio":0.5815706151257927},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NCI\",,,,,undefined,":{"symbol":"NCI","floatShares":1726200,"roa":"6.28%","roe":"58.31%","lyrEps":0.031396,"volumeRatio":0.5815706151257927,"shares":20320000,"dividePrice":0.2,"high":0.328,"amplitude":0.088106,"preClose":0.3178,"low":0.3,"week52Low":0.28,"pbRate":"1.00","psRate":"0.29","week52High":1.8,"institutionHeld":0.7857,"latestPrice":0.3175,"eps":0.076408,"divideRate":0.629921,"volume":29864,"delay":0,"ttmEps":0.076408,"open":0.32,"prevYearClose":0.66,"fiveDayClose":0.371,"twentyDayClose":0.4299,"sixtyDayClose":0.5374},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NCI\",pageSize:20,pageCount:4,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2501772285","title":"SELLAS Announces Key Business Objectives for 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2501772285","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501772285?lang=en_us&edition=fundamental","pubTime":"2025-01-08 21:20","pubTimestamp":1736342400,"startTime":"0","endTime":"0","summary":"- Independent Data Monitoring Committee to Perform Interim Analysis of Phase 3 REGAL Study in January 2025 - - SLS009: Full Topline Phase 2 Data in Acute Myeloid Leukemia and FDA Regulatory Review Exp","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/01/08/3006252/0/en/SELLAS-Announces-Key-Business-Objectives-for-2025.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4533","BK4109","INN","SLS","BK4181","BK4183","LU0985320562.USD","LU2355687059.USD","BK4218","LU2463526074.USD","BK4107","BK4202","BK4588","LU1571399168.USD","NCI","LU1699723380.USD","BK4139","ASH","BK4585","ODD","ALL"],"gpt_icon":0},{"id":"2501272170","title":"Gain Therapeutics Announces Formation of Clinical Advisory Board to Support Continued Advancement of Lead Drug Candidate GT-02287","url":"https://stock-news.laohu8.com/highlight/detail?id=2501272170","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501272170?lang=en_us&edition=fundamental","pubTime":"2025-01-08 21:00","pubTimestamp":1736341200,"startTime":"0","endTime":"0","summary":"BETHESDA, Md., Jan. 08, 2025  -- Gain Therapeutics, Inc.  , a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced the formation of its Clinical Advisory Board  to support the continued development of the Company’s lead drug candidate, GT-02287, in Parkinson’s disease. The CAB is composed of leading experts in Parkinson’s disease trial design, genetics, and biomarkers and will work closely with Gain leadership to progress GT-02287 through potential Phase 2 and Phase 3 clinical development.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/gain-therapeutics-announces-formation-clinical-130000745.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CAB","BK4202","BK4023","BK4585","BK4119","LENZ","GANX","NCI","BK4139","GT","LU1169589451.USD","LU1169590202.USD","PD","BK4588"],"gpt_icon":0},{"id":"2501159367","title":"Shell fourth quarter 2024 update note","url":"https://stock-news.laohu8.com/highlight/detail?id=2501159367","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501159367?lang=en_us&edition=fundamental","pubTime":"2025-01-08 15:00","pubTimestamp":1736319600,"startTime":"0","endTime":"0","summary":"The following is an update to the fourth quarter 2024 outlook and gives an overview of our current expectations for the fourth quarter. Outlooks presented may vary from the actual fourth quarter 2024 ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/01/08/3005966/0/en/Shell-fourth-quarter-2024-update-note.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4202","NCI","BK4006","MT","BK4561"],"gpt_icon":0},{"id":"2501206734","title":"Guardant Health Shield test selected for use in NCI Vanguard study","url":"https://stock-news.laohu8.com/highlight/detail?id=2501206734","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501206734?lang=en_us&edition=fundamental","pubTime":"2025-01-07 21:10","pubTimestamp":1736255443,"startTime":"0","endTime":"0","summary":"Guardant Health (GH) announced the National Cancer Institute, or NCI, has selected the company’s Shield multi-cancer detection test for use in its ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/guardant-health-shield-test-selected-for-use-in-nci-vanguard-study?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/guardant-health-shield-test-selected-for-use-in-nci-vanguard-study?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4202","GH","BK4585","NCI","BK4588","BK4535","BK4551","BK4196"],"gpt_icon":0},{"id":"2501206969","title":"MD Anderson and Myriad Genetics form strategic alliance to evaluate clinical utility of Myriad’s molecular residual disease assay","url":"https://stock-news.laohu8.com/highlight/detail?id=2501206969","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501206969?lang=en_us&edition=fundamental","pubTime":"2025-01-07 21:00","pubTimestamp":1736254800,"startTime":"0","endTime":"0","summary":"HOUSTON and SALT LAKE CITY, Jan.  07, 2025  (GLOBE NEWSWIRE) -- The University of Texas MD Anderson Cancer Center and Myriad Genetics, Inc. today announced a five-year strategic alliance to accelerate","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/01/07/3005354/15459/en/MD-Anderson-and-Myriad-Genetics-form-strategic-alliance-to-evaluate-clinical-utility-of-Myriad-s-molecular-residual-disease-assay.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MYGN","MD","NCI","BK4196","BK4139","BK4202"],"gpt_icon":0},{"id":"2501247267","title":"BerGenBio Announces First Patient Entered Into Advanced Adenocarcinoma Lung Cancer Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2501247267","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501247267?lang=en_us&edition=fundamental","pubTime":"2025-01-07 14:26","pubTimestamp":1736231160,"startTime":"0","endTime":"0","summary":"BERGEN, Norway, Jan. 7, 2025 /PRNewswire/ --BerGenBio ASA , a clinical-stage biopharmaceutical company developing the novel, selective AXL kinase inhibitor bemcentinib for lung cancer announced today that the first patient has been included in a clinical trial sponsored by the Mays Cancer Center at The University of Texas Health Science Center at San Antonio . The study is led by Josephine A. Taverna, MD, a thoracic oncologist at the Mays Cancer Center and Associate Professor in the Division of Hematology and Oncology at UT Health San Antonio.\"Dr. Taverna's research has shown that AXL and JAK-STAT3 work in tandem to transmit signals promoting tumor growth and metastasis in advanced lung cancer. We are pleased to see this research advancing into clinical application and believe this study aligns closely with BerGenBio's strategic focus on addressing the significant unmet needs of lung cancer patients, including first-line Non-Small Cell Lung Cancer patients with mutations in the STK11 g","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/bergenbio-announces-first-patient-entered-062600576.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/bergenbio-announces-first-patient-entered-062600576.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","IE00B66KJ199.SGD","IE00B19Z4B17.USD","BK4202","BK4157","IE00B7SZL793.SGD","NCI","BRRGF","IE0031619046.USD","AEIS"],"gpt_icon":0},{"id":"2493237209","title":"Neo-Concept International Group Holdings First Half 2024 Earnings: EPS: HK$0.075 (vs HK$0.29 loss in 1H 2023)","url":"https://stock-news.laohu8.com/highlight/detail?id=2493237209","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493237209?lang=en_us&edition=fundamental","pubTime":"2024-12-21 20:56","pubTimestamp":1734785786,"startTime":"0","endTime":"0","summary":"Neo-Concept International Group Holdings  First Half 2024 Results. Profit margin: 1.8% . The move to profitability was primarily driven by lower expenses.NasdaqCM:NCI Earnings and Revenue History December 21st 2024. All figures shown in the chart above are for the trailing 12 month  period. We don't want to rain on the parade too much, but we did also find 3 warning signs for Neo-Concept International Group Holdings that you need to be mindful of.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/5Vpve0Pc2F3m_L3fs2p_dQ--~B/aD02MzY7dz05NDU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/78a8c60a6283aea0450523395306d38c","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/5Vpve0Pc2F3m_L3fs2p_dQ--~B/aD02MzY7dz05NDU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/78a8c60a6283aea0450523395306d38c"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/neo-concept-international-group-holdings-125626676.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["NCI"],"gpt_icon":0},{"id":"2492317646","title":"Neo-Concept International Group H1 2024 EPS $0.01; Revenue $10.15M","url":"https://stock-news.laohu8.com/highlight/detail?id=2492317646","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492317646?lang=en_us&edition=fundamental","pubTime":"2024-12-19 22:19","pubTimestamp":1734617953,"startTime":"0","endTime":"0","summary":"Neo-Concept International Group H1 2024 EPS $0.01; Revenue $10.15M","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/12/42589105/neo-concept-international-group-h1-2024-eps-0-01-revenue-10-15m","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Neo-Concept International Group H1 2024 EPS $0.01; Revenue $10.15M","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NCI"],"gpt_icon":0},{"id":"2492175157","title":"Neo-Concept International Group Holdings Limited Announces First Half 2024 Unaudited Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2492175157","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492175157?lang=en_us&edition=fundamental","pubTime":"2024-12-19 22:00","pubTimestamp":1734616809,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241219:nTUA7SDCJH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4202","NCI"],"gpt_icon":0},{"id":"2492959911","title":"Plus Therapeutics Presents Positive ReSPECT-LM Phase 1 Interim Data for Breast Cancer Patients with Leptomeningeal Metastases at the 2024 San Antonio Breast Cancer Symposium","url":"https://stock-news.laohu8.com/highlight/detail?id=2492959911","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492959911?lang=en_us&edition=fundamental","pubTime":"2024-12-17 20:30","pubTimestamp":1734438600,"startTime":"0","endTime":"0","summary":"Single intrathecal dose of Rhenium (186Re) Obisbemeda delivers favorable responses in cerebrospinal fluid circulating tumor cell count, imaging, and clinical evaluation Both single-dose and multiple-d","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/12/17/2998156/0/en/Plus-Therapeutics-Presents-Positive-ReSPECT-LM-Phase-1-Interim-Data-for-Breast-Cancer-Patients-with-Leptomeningeal-Metastases-at-the-2024-San-Antonio-Breast-Cancer-Symposium.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CSF","BK4202","BK4139","LENZ","NCI"],"gpt_icon":0},{"id":"2490866155","title":"LYNPARZA® (olaparib) demonstrated clinically meaningful prolonged survival benefit in early breast cancer in OlympiA Phase III trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2490866155","media":"Business Wire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490866155?lang=en_us&edition=fundamental","pubTime":"2024-12-11 23:15","pubTimestamp":1733930100,"startTime":"0","endTime":"0","summary":"First and only PARP inhibitor to improve survival in early breast cancer. WILMINGTON, Del., December 11, 2024----Updated results from the OlympiA Phase III trial showed AstraZeneca and Merck & Co., Inc’s, known as MSD outside of the US and Canada, LYNPARZA  demonstrated sustained, clinically meaningful improvements in overall survival , invasive disease-free survival  and distant disease-free survival  at six years for patients with germline BRCA-mutated  HER2-negative high-risk early breast cancer.Eliav Barr, Senior Vice President, Head of Global Clinical Development and C","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/ARG9pBkQU.InVGzB47YqBg--~B/aD00NzU7dz0xNDM4O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/8ec7ccdd0c2fab1da78e61eea7bf33a6","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/ARG9pBkQU.InVGzB47YqBg--~B/aD00NzU7dz0xNDM4O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/8ec7ccdd0c2fab1da78e61eea7bf33a6"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/lynparza-olaparib-demonstrated-clinically-meaningful-151500770.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["OS","BK4114","III","BK4104","BK4220","LU2462157665.USD","LU2023250504.SGD","BK4202","LU2456880835.USD","URI","LU1974910355.USD","BK4097","LU1829250122.USD","LU0109394709.USD","BK4007","LU1917777945.USD","LU0889565916.HKD","BK4203","BK4516","LU2023250843.SGD","BIG","LU2417539215.USD","NCI","LU2236285917.USD","HR","BK4225","LU1721428933.USD","BK4585","LU0320765992.SGD","LU2106854487.HKD","BK4588","BK4134","BK4568","AZN"],"gpt_icon":0},{"id":"2490071966","title":"Press Release: Shell plc Third Quarter 2024 Euro and GBP Equivalent Dividend Payments","url":"https://stock-news.laohu8.com/highlight/detail?id=2490071966","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490071966?lang=en_us&edition=fundamental","pubTime":"2024-12-09 15:00","pubTimestamp":1733727600,"startTime":"0","endTime":"0","summary":"SHELL PLC THIRD QUARTER 2024 EURO AND GBP EQUIVALENT DIVIDEND PAYMENTS. The Board of Shell plc today announced the pounds sterling and euro equivalent dividend payments in respect of the third quarter 2024 interim dividend, which was announced on October 31, 2024 at US$0.344 per ordinary share.Shareholders have been able to elect to receive their dividends in US dollars, euros or pounds sterling. Holders of ordinary shares who have validly submitted US dollars, euros or pounds sterling currency elections by November 29, 2024 will be entitled to a dividend of US$0.344, EUR0.3262 or 27.03p per ordinary share, respectively.Absent any valid election to the contrary, persons holding their ordinary shares through Euroclear Nederland will receive their dividends in euros at the euro rate per ordinary share shown above. Absent any valid election to the contrary, shareholders  and persons holding their shares through the Shell Corporate Nominee will receive their dividends in pounds sterling, a","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0320765646.SGD","LU0278409577.USD","LU0300736492.USD","NCI","BK4202","LU1162221912.USD","BK4588","LU2236285917.USD","BK4201","LU0300736062.USD","SHEL","LU0098860793.USD","BK4585"],"gpt_icon":0},{"id":"2489222687","title":"BLINCYTO® (BLINATUMOMAB) ADDED TO CHEMOTHERAPY SIGNIFICANTLY IMPROVES SURVIVAL IN NEWLY DIAGNOSED PEDIATRIC PATIENTS WITH B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL)","url":"https://stock-news.laohu8.com/highlight/detail?id=2489222687","media":"PR Newswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489222687?lang=en_us&edition=fundamental","pubTime":"2024-12-07 23:00","pubTimestamp":1733583600,"startTime":"0","endTime":"0","summary":"Phase 3 Study Results Demonstrated Three Year, Disease-Free Survival of 96%. THOUSAND OAKS, Calif., Dec. 7, 2024 /PRNewswire/ -- Amgen  today announcednew data demonstrating that adding BLINCYTO  to chemotherapy significantly improves disease-free survival  in newly diagnosed pediatric patients with National Cancer Institute  standard risk  B-cell acute lymphoblastic leukemia  of average or higher risk of relapse. The data are from a Phase 3 study  conducted by the Children's Oncology Group. The results were simultaneously publishedin the New England Journal of Medicine and will be presented during the plenary session on Sunday, Dec. 8, at 2 p.m. PT at the 66th American Society of Hematology  Annual Meeting & Exposition in San Diego.The addition of BLINCYTO to chemotherapy in standard risk patients resulted in outcomes similar to those previously achieved i","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/fXOCbBYEhALvuJbXuwlWEQ--~B/aD0yMjU7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/a085ee332e8e3e11ca5c7e5584018b12","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/fXOCbBYEhALvuJbXuwlWEQ--~B/aD0yMjU7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/a085ee332e8e3e11ca5c7e5584018b12"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/blincyto-blinatumomab-added-chemotherapy-significantly-150000076.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/blincyto-blinatumomab-added-chemotherapy-significantly-150000076.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["NCI","BK4135","AMGN","DFS","BK4006","BK4139","LU0122379950.USD","LU2125910500.SGD","IE00B2B36J28.USD","LU1023059063.AUD","LU0106831901.USD","AST","BK4196","IE0031619046.USD","IE00BFTCPJ56.SGD","BK4533","CELL","LU1059921491.USD","TLS","IE00B19Z3B42.SGD","IE00B19Z4B17.USD","LU1571399168.USD","LU0170899867.USD","ALT","ASH","MAS","IE00BJJMRZ35.SGD","LU1596574779.USD","BK4156","CI","LU2360107671.USD","LU1261432733.SGD","BK4097","LU0985320562.USD","BK4166","BK4588","HR","LU1861217088.USD","IE00B7SZL793.SGD","CLS","IE00B19Z3581.USD","IE0002141913.USD","SR","LU1620156130.USD","CRS","LU1165135440.EUR","CNS","ALL","LU1861220207.SGD"],"gpt_icon":0},{"id":"2488595160","title":"Plus Therapeutics to Showcase ReSPECT-LM Phase 1 Interim Data for Leptomeningeal Metastases at the 2024 San Antonio Breast Cancer Symposium","url":"https://stock-news.laohu8.com/highlight/detail?id=2488595160","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488595160?lang=en_us&edition=fundamental","pubTime":"2024-12-04 20:30","pubTimestamp":1733315400,"startTime":"0","endTime":"0","summary":"Company to present ReSPECT-LM Phase 1 trial data on Rhenium (186Re) Obisbemeda with a focus on treating leptomeningeal metastases (LM) in breast cancer patients AUSTIN, Texas, Dec.  04, 2024  (GLOBE N","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/12/04/2991382/0/en/Plus-Therapeutics-to-Showcase-ReSPECT-LM-Phase-1-Interim-Data-for-Leptomeningeal-Metastases-at-the-2024-San-Antonio-Breast-Cancer-Symposium.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","BK4202","BK4135","NCI","BK4139","CSF","CNS"],"gpt_icon":0},{"id":"2488694991","title":"Press Release: Shell completes sale of Sinco pipeline system and Colex terminal to Edgewater Midstream","url":"https://stock-news.laohu8.com/highlight/detail?id=2488694991","media":"Dow Jones","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488694991?lang=en_us&edition=fundamental","pubTime":"2024-12-03 23:01","pubTimestamp":1733238060,"startTime":"0","endTime":"0","summary":"HOUSTON, Dec. 3, 2024 /PRNewswire/ -- Shell Pipeline Company LP and. Triton West LLC, subsidiaries of Shell USA, Inc. , have completed. the previously announced 100% sale of the Sinco pipeline system and. Colex terminal to a subsidiary of Edgewater Midstream LLC .This sale simplifies Shell's portfolio, enabling redeployment of capital. Following the sale of Shell's equity share in the Deer Park Refinery in. 2022, these assets were non-integrated and no longer fit within Shell's. -- The Sinco pipeline system and the Colex terminal are located in the. Houston Ship Channel area and have historically been operated as. -- In 2022, Shell completed the sale of its equity share in the Deer Park. Refinery to Pemex, rendering the Sinco pipeline and the Colex terminal. -- Both Shell Pipeline Company LP and Triton West LLC are subsidiaries of. pipelines and terminals in proximity to major North American petroleum. annually through its vast network of pipelines and tank farms, ensuring. Shell's U.S","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","NCI","BK4201","LU0300736492.USD","LU0300736062.USD","BK4588","BK4202","LU0320765646.SGD","LU1162221912.USD","SHEL","LU2236285917.USD","LU0278409577.USD","LU0098860793.USD"],"gpt_icon":0},{"id":"2488910690","title":"Kairos Pharma Adds City of Hope Cancer Center for Phase 2 ENV105 Clinical Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2488910690","media":"Business Wire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488910690?lang=en_us&edition=fundamental","pubTime":"2024-12-03 21:30","pubTimestamp":1733232600,"startTime":"0","endTime":"0","summary":"ENV105 can potentially address resistance in a wide range of cancers as they become resistant to standard treatments.LOS ANGELES, December 03, 2024----Kairos Pharma Ltd. , a clinical-stage biopharmaceutical company developing therapies to surmount current cancer drug resistance and immune suppression, today announces the addition of City of Hope Cancer Center in Duarte, California to the Phase 2 clinical trial for ENV105 for castrate-resistant prostate cancer patients.City of Hope Cancer Center is the first of several planned new centers to be added in the coming weeks to support the Company’s randomized trial for patients receiving either apalutamide or apalutamide+ENV105 combination therapy. The additional centers allow Kairos Pharma to test ENV105 in a broader patient population to identify blood markers that could help select patients expected to benefit most from ENV105 treatment. The trial is supported by Kairos Pharma Ltd. and a grant from the National Cancer Institute .This pre","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/ijWwXjgPhNVNW.SLpaS2oQ--~B/aD01MTI7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/a58eb5cf675810d6dd8fe6b86f3e5cc6","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/ijWwXjgPhNVNW.SLpaS2oQ--~B/aD01MTI7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/a58eb5cf675810d6dd8fe6b86f3e5cc6"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/kairos-pharma-adds-city-hope-133000317.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["HOPE","BK4202","BK4139","KAIR","BK4211","CHCO","KAPA","NCI"],"gpt_icon":0},{"id":"2488728912","title":"Aptose and NCI Collaborate on Cancer Drug Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2488728912","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488728912?lang=en_us&edition=fundamental","pubTime":"2024-12-03 21:09","pubTimestamp":1733231387,"startTime":"0","endTime":"0","summary":"Aptose Biosciences (TSE:APS) has released an update. Aptose Biosciences has partnered with the National Cancer Institute to develop tuspetinib for ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/aptose-and-nci-collaborate-on-cancer-drug-trials?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/aptose-and-nci-collaborate-on-cancer-drug-trials?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NCI","BK4202"],"gpt_icon":0},{"id":"2488115519","title":"BRIEF-Aptose Signs CRADA with NCI to Develop Tuspetinib for AML and MDS in Newly Launched MyeloMATCH Precision Medicine Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2488115519","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488115519?lang=en_us&edition=fundamental","pubTime":"2024-12-03 20:40","pubTimestamp":1733229604,"startTime":"0","endTime":"0","summary":"Dec 3 (Reuters) - Aptose Biosciences Inc   :   * APTOSE SIGNS CRADA WITH NCI TO DEVELOP TUSPETINIB FOR AML AND MDS IN NEWLY LAUNCHED MYELOMATCH PRECISION MEDICINE TRIALSSource text:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NCI","BK4202"],"gpt_icon":0},{"id":"2488911548","title":"Aptose Biosciences signs CRADA with NCI to develop tuspetinib for AML, MDS","url":"https://stock-news.laohu8.com/highlight/detail?id=2488911548","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488911548?lang=en_us&edition=fundamental","pubTime":"2024-12-03 20:35","pubTimestamp":1733229308,"startTime":"0","endTime":"0","summary":"Aptose Biosciences (APTO) announced that the National Cancer Institute, NCI, part of the National Institutes of Health, and Aptose Biosciences Inc....","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/aptose-biosciences-signs-crada-with-nci-to-develop-tuspetinib-for-aml-mds?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/aptose-biosciences-signs-crada-with-nci-to-develop-tuspetinib-for-aml-mds?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4202","APTO","BK4139","NCI"],"gpt_icon":0},{"id":"2488553911","title":"Plus Therapeutics Expands Strategic Agreement with Telix IsoTherapeutics Group for Rhenium-186 Radioisotope Supply","url":"https://stock-news.laohu8.com/highlight/detail?id=2488553911","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488553911?lang=en_us&edition=fundamental","pubTime":"2024-12-03 20:30","pubTimestamp":1733229000,"startTime":"0","endTime":"0","summary":"Five-year renewable agreement secures reliable cGMP rhenium-186 (Re-186) supply for late-stage clinical and commercial forecastsAUSTIN, Texas, Dec.  03, 2024  (GLOBE NEWSWIRE) -- Plus Therapeutics, In","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/12/03/2990474/0/en/Plus-Therapeutics-Expands-Strategic-Agreement-with-Telix-IsoTherapeutics-Group-for-Rhenium-186-Radioisotope-Supply.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MSA","BK4143","NCI","LU1815336091.USD","LU0728928796.USD","BK4202","LU0053671581.USD","LU2125909759.SGD","LENZ","LU1923622291.USD","LU0757428866.USD","BK4139","LU2125909916.SGD"],"gpt_icon":0}],"pageSize":20,"totalPage":5,"pageCount":4,"totalSize":91,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NCI\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NCI\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"NCI\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/NCI\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"NCI","date":"2025-05-06","current":4.548188,"percent":0.070539,"low":-615.963293,"twenty":6.285272,"median":15.512604,"eighty":24.341599,"high":50.080918,"avg":6.828591,"sd":51.936132,"marketCap":6457696},"quantilePoints":[{"date":"2024-04-26","current":-152.934443,"twenty":-421.533502,"median":-222.424043,"eighty":-152.416021,"marketCap":47955200},{"date":"2024-05-03","current":-75.704037,"twenty":-208.526123,"median":-121.807344,"eighty":-81.702314,"marketCap":23774400},{"date":"2024-05-10","current":-74.39805,"twenty":-152.15681,"median":-81.565326,"eighty":-71.297323,"marketCap":23368000},{"date":"2024-05-17","current":36.631419,"twenty":-133.739762,"median":-74.39805,"eighty":-23.514082,"marketCap":20726400},{"date":"2024-05-24","current":30.19238,"twenty":-105.051475,"median":-71.169081,"eighty":36.421773,"marketCap":17068800},{"date":"2024-05-31","current":28.783514,"twenty":-89.228644,"median":-65.79629,"eighty":35.854613,"marketCap":16256000},{"date":"2024-06-07","current":28.579978,"twenty":-81.702314,"median":24.992177,"eighty":34.642796,"marketCap":16154400},{"date":"2024-06-14","current":31.815689,"twenty":-79.845114,"median":25.185699,"eighty":33.392506,"marketCap":17983200},{"date":"2024-06-21","current":25.826264,"twenty":-75.704037,"median":25.951163,"eighty":31.815689,"marketCap":14610080},{"date":"2024-06-28","current":24.010495,"twenty":-75.181642,"median":25.826264,"eighty":31.166365,"marketCap":13573760},{"date":"2024-07-05","current":21.847045,"twenty":-74.134092,"median":24.992177,"eighty":30.05711,"marketCap":12350496},{"date":"2024-07-12","current":24.005484,"twenty":-72.824666,"median":24.22361,"eighty":29.406809,"marketCap":13573760},{"date":"2024-07-15","current":23.309684,"twenty":-72.571072,"median":24.010495,"eighty":29.29759,"marketCap":13183616},{"date":"2024-08-02","current":17.799213,"twenty":-72.317479,"median":24.00799,"eighty":29.18837,"marketCap":10054336},{"date":"2024-08-09","current":15.712059,"twenty":-71.040839,"median":23.456094,"eighty":28.858081,"marketCap":8900160},{"date":"2024-08-16","current":14.71315,"twenty":-69.000048,"median":23.177414,"eighty":28.661392,"marketCap":8331200},{"date":"2024-08-23","current":15.475212,"twenty":-65.359249,"median":22.360574,"eighty":28.479131,"marketCap":8761984},{"date":"2024-08-30","current":15.211668,"twenty":-16.796281,"median":21.73132,"eighty":28.375818,"marketCap":8611616},{"date":"2024-09-06","current":15.60865,"twenty":14.533412,"median":17.564477,"eighty":28.127716,"marketCap":8839200},{"date":"2024-09-13","current":18.316746,"twenty":14.714645,"median":17.091682,"eighty":27.226945,"marketCap":10363200},{"date":"2024-09-20","current":30.136472,"twenty":14.729124,"median":17.451967,"eighty":27.226945,"marketCap":17068800},{"date":"2024-09-27","current":18.155945,"twenty":14.756986,"median":17.799213,"eighty":26.316487,"marketCap":10304272},{"date":"2024-10-04","current":24.668714,"twenty":14.779837,"median":18.134605,"eighty":27.226945,"marketCap":14022832},{"date":"2024-10-11","current":19.411936,"twenty":14.800605,"median":18.316746,"eighty":26.316487,"marketCap":11029696},{"date":"2024-10-18","current":27.159393,"twenty":14.841085,"median":19.188638,"eighty":26.316487,"marketCap":15422880},{"date":"2024-10-25","current":22.801653,"twenty":14.96086,"median":20.067961,"eighty":27.538745,"marketCap":12954000},{"date":"2024-10-31","current":26.444278,"twenty":15.097424,"median":21.615595,"eighty":28.23974,"marketCap":15016480},{"date":"2024-11-08","current":25.398607,"twenty":15.188698,"median":21.880614,"eighty":27.72766,"marketCap":14427200},{"date":"2024-11-15","current":22.207911,"twenty":15.214052,"median":22.207911,"eighty":27.409251,"marketCap":12598400},{"date":"2024-11-22","current":20.742686,"twenty":15.227723,"median":22.212919,"eighty":27.092873,"marketCap":11765280},{"date":"2024-11-29","current":19.71984,"twenty":15.244259,"median":22.031838,"eighty":26.826792,"marketCap":11184128},{"date":"2024-12-06","current":19.342155,"twenty":15.419442,"median":21.847045,"eighty":26.825987,"marketCap":10972800},{"date":"2024-12-13","current":18.931587,"twenty":15.475212,"median":20.935809,"eighty":26.444278,"marketCap":10749280},{"date":"2024-12-20","current":16.81288,"twenty":15.549996,"median":20.067961,"eighty":26.379894,"marketCap":9550400},{"date":"2024-12-27","current":7.581302,"twenty":15.240125,"median":20.023482,"eighty":26.25308,"marketCap":10741152},{"date":"2025-01-03","current":8.618162,"twenty":15.140189,"median":19.71984,"eighty":26.21899,"marketCap":12196064},{"date":"2025-01-10","current":10.05795,"twenty":14.800605,"median":19.685908,"eighty":26.181452,"marketCap":14224000},{"date":"2025-01-17","current":8.786233,"twenty":14.714645,"median":19.468094,"eighty":26.125394,"marketCap":12415520},{"date":"2025-01-24","current":9.780279,"twenty":10.25185,"median":19.354401,"eighty":26.087984,"marketCap":13817600},{"date":"2025-01-31","current":8.55813,"twenty":9.931507,"median":18.990258,"eighty":25.926183,"marketCap":12088368},{"date":"2025-02-07","current":8.034161,"twenty":9.67709,"median":18.942456,"eighty":25.806345,"marketCap":11354816},{"date":"2025-02-14","current":7.429972,"twenty":9.170381,"median":18.736365,"eighty":25.661057,"marketCap":10499344},{"date":"2025-02-21","current":7.182682,"twenty":8.786233,"median":18.611629,"eighty":25.398607,"marketCap":10166096},{"date":"2025-02-28","current":6.088957,"twenty":8.49005,"median":18.298903,"eighty":25.263582,"marketCap":8617712},{"date":"2025-03-07","current":6.285152,"twenty":8.101774,"median":18.113266,"eighty":25.252549,"marketCap":8900160},{"date":"2025-03-14","current":5.596631,"twenty":7.768683,"median":17.68941,"eighty":25.185699,"marketCap":7924800},{"date":"2025-03-21","current":6.28575,"twenty":7.480228,"median":17.54621,"eighty":25.06182,"marketCap":8900160},{"date":"2025-03-28","current":6.3175,"twenty":7.319362,"median":17.202773,"eighty":24.992177,"marketCap":8940800},{"date":"2025-04-04","current":6.433722,"twenty":7.066391,"median":16.81288,"eighty":24.761928,"marketCap":9104010},{"date":"2025-04-11","current":7.43656,"twenty":6.901399,"median":16.523806,"eighty":24.668714,"marketCap":10546080},{"date":"2025-04-17","current":5.733501,"twenty":6.823071,"median":16.327956,"eighty":24.52062,"marketCap":8128000},{"date":"2025-04-25","current":5.587097,"twenty":6.410478,"median":15.712059,"eighty":24.4461,"marketCap":7924800},{"date":"2025-05-02","current":4.29948,"twenty":6.295892,"median":15.579323,"eighty":24.363962,"marketCap":6100064},{"date":"2025-05-06","current":4.548188,"twenty":6.285272,"median":15.512604,"eighty":24.341599,"marketCap":6457696}],"updateTime":1746624367594}}}